You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《新股消息》瑞科生物-B(02179.HK)今起招股 入場費12,525元
阿思達克 03-21 09:29
疫苗公司瑞科生物-B(02179.HK)公佈招股詳情,擬全球發售3,085.45萬股,香港公開發售佔一成,國際發售佔九成,每股招股價24.8元,每手500計,一手入場費12,524.97元。該股今日(21日)起超股,週四(24日)中午截止,預期下週四(31日)掛牌。聯席保薦人爲摩根士丹利、招銀國際及中信證券。 基石投資者包括揚子江香港、Harvest、SCHP及紅杉資本中國轄下Sequoia Capital China Growth,合共認購公司5,300萬美元股份。 公司預期是次上市淨集約6.72億元,約47.3%擬用於繼續優化、開發及商業化其HPV疫苗管線,包括核心產品(重組HPV九價疫苗REC603);約17.7%用於新冠肺炎疫苗(即ReCOV)的臨牀前及臨牀研究、註冊;約21.1%用於其他候選疫苗的臨牀前及臨牀研究、註冊,包括結核病疫苗REC606及REC607、重組四價流感疫苗REC617及重組手足口病四價疫苗REC605等;約6.7%用於進一步加強研發能力及提高營運效率;約7.2%用作營運資金及一般企業用途。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account